Zomedica Corp. [AMEX: ZOM] loss -1.01% or -0.01 points to close at $0.50 with a heavy trading volume of 13825035 shares. The company report on October 4, 2021 that Zomedica Appoints Larry Heaton as President and Announces CEO Succession Plan.
Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, announced that Larry Heaton has been appointed President effective October 1, 2021. Mr. Heaton will assume the role of Chief Executive Officer upon the retirement of current Chief Executive Officer Robert Cohen on October 31, 2021. Following his retirement, Mr. Cohen will remain on the Board of Directors of Zomedica.
Mr. Heaton brings to Zomedica more than 35 years of executive leadership and operations experience from the medical device and biotechnology industries with an extensive focus on commercialization and business development in both large cap and early-stage medical device companies. Mr. Heaton was awarded a Bachelor of Arts degree from Eastern Illinois University, and is an inventor on several U.S. patents. He has served as a member of the board of several international medical societies and foundations, including the MITAC Board for the commercialization of NASA technology via partnerships with the medical industry.
It opened the trading session at $0.51, the shares rose to $0.51 and dropped to $0.50, the range by which the price of stock traded the whole day. The daily chart for ZOM points out that the company has recorded -55.75% loss over the past six months. However, it is still -733.33% lower than its most recent low trading price.
If we look at the average trading volume of 27.22M shares, ZOM reached to a volume of 13825035 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Zomedica Corp. [ZOM]:
The Average True Range (ATR) for Zomedica Corp. is set at 0.03, with the Price to Sales ratio for ZOM stock in the period of the last 12 months amounting to 16706.58. The Price to Book ratio for the last quarter was 1.79, with the Price to Cash per share for the same quarter was set at 0.28.
Trading performance analysis for ZOM stock
Zomedica Corp. [ZOM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.96. With this latest performance, ZOM shares dropped by -11.50% in over the last four-week period, additionally sinking by -55.75% over the last 6 months – not to mention a rise of 476.04% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 42.84, with the RSI for the last a single of trading hit 41.10, and the three-weeks RSI is set at 43.32 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.5454, while it was recorded at 0.5090 for the last single week of trading, and 1.0063 for the last 200 days.
Zomedica Corp. [ZOM]: A deeper dive into fundamental analysis
Return on Total Capital for ZOM is now -50.05, given the latest momentum, and Return on Invested Capital for the company is -51.08. Return on Equity for this stock declined to -51.94, with Return on Assets sitting at -48.09. When it comes to the capital structure of this company, Zomedica Corp. [ZOM] has a Total Debt to Total Equity ratio set at 2.96. Additionally, ZOM Total Debt to Total Capital is recorded at 2.88, with Total Debt to Total Assets ending up at 2.82. Long-Term Debt to Equity for the company is recorded at 2.13, with the Long-Term Debt to Total Capital now at 1.68.
Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 81.40 and a Current Ratio set at 81.70.
An analysis of insider ownership at Zomedica Corp. [ZOM]
There are presently around $65 million, or 15.60% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 42,501,241, which is approximately 4.231% of the company’s market cap and around 0.30% of the total institutional ownership; STATE STREET CORP, holding 18,366,408 shares of the stock with an approximate value of $9.18 million in ZOM stocks shares; and BLACKROCK INC., currently with $8.66 million in ZOM stock with ownership of nearly 0.899% of the company’s market capitalization.
Positions in Zomedica Corp. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 57 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 40,222,846 shares. Additionally, 40 investors decreased positions by around 10,892,449 shares, while 34 investors held positions by with 79,687,665 shares. The mentioned changes placed institutional holdings at 130,802,960 shares, according to the latest SEC report filing. ZOM stock had 32 new institutional investments in for a total of 19,432,606 shares, while 26 institutional investors sold positions of 8,415,621 shares during the same period.